Category: Latest News
-
Forward Industries Files $4 Billion Program Focused on Solana
Forward Industries (NASDAQ:FORD), a Nasdaq-listed design company that has repositioned itself as a corporate treasury focused on Solana (COIN:SOLUSD), has filed a share offering program of up to $4 billion with the SEC. The at-the-market (ATM) program will allow the company to gradually sell shares depending on market conditions, through Cantor Fitzgerald. The company emphasized…
-
Metaplanet Creates New Bitcoin Subsidiaries in the U.S. and Japan
Metaplanet (USOTC:MTPLF), often called the “MicroStrategy of Asia,” announced a major expansion of its Bitcoin (COIN:BTCUSD)-related operations with the creation of new subsidiaries in the United States and Japan. In the U.S., the company established Metaplanet Income Corp., headquartered in Miami. The subsidiary, fully owned by Metaplanet Holdings Inc., will focus on generating Bitcoin income…
-
U.S. Housing Starts Fall Sharply in August, Missing Forecasts
After two straight months of growth in residential construction, new government data showed a surprisingly steep pullback in U.S. housing activity during August. The Commerce Department reported Wednesday that housing starts dropped 8.5% to an annualized pace of 1.307 million units. That compares with a revised 1.429 million rate in July, which had marked a…
-
Dow Jones, S&P, Nasdaq, Wall Street Futures Signal Flat Start Amid Fed Decision Anticipation
U.S. stock index futures were little changed early Wednesday, pointing to a muted opening as investors brace for the Federal Reserve’s policy announcement later in the day. The cautious mood mirrors Tuesday’s lackluster action, when major averages ended slightly lower after early gains faded. Market participants are largely in wait-and-see mode ahead of the Fed’s…
-
Deutsche Bank projects gold could reach $4,000 per ounce in 2026
Deutsche Bank analysts have increased their 2026 gold price forecast, citing strong recent gains in the metal and expectations for potential U.S. interest rate cuts, as well as ongoing questions over the Federal Reserve’s independence. In a client briefing, the team led by Michael Hsueh raised the average projected price for 2026 to $4,000 per…
-
WTO report: AI could lift global trade by nearly 40% by 2040
Artificial intelligence (AI) has the potential to expand the value of international trade in goods and services by almost 40% by 2040, according to the World Trade Report 2025, released Wednesday by the World Trade Organization (WTO). The report outlines scenarios in which global trade grows between 34% and 37%, depending on the pace of…
-
Novo Nordisk targets full U.S. rollout of oral semaglutide in 2026
Novo Nordisk (NYSE:NVO) is planning a comprehensive launch of its oral semaglutide in the United States at the start of 2026, the company’s head of product and portfolio strategy confirmed on Wednesday. Speaking to Reuters, Products and Portfolio Strategy Chief Helfgott highlighted that the company sees a “very compelling offer” with its Wegovy pill compared…
-
China Orders Local Firms to Halt Purchases of Nvidia AI Chips
China’s internet regulator has instructed major domestic technology companies to stop buying chips from Nvidia (NASDAQ:NVDA), the semiconductor leader favored in artificial intelligence, according to the Financial Times. Sources familiar with the matter told the FT that firms including ByteDance, owner of TikTok, and e-commerce giant Alibaba were directed by the Cyberspace Administration of China…
-
Dollar Climbs from Two-Month Lows as Markets Await Fed Decision; Sterling Dips
The U.S. dollar gained slightly on Wednesday as investors positioned ahead of the Federal Reserve’s anticipated interest rate announcement, though it remained under pressure after recent losses. By 04:10 ET (08:10 GMT), the Dollar Index, which measures the greenback against six major currencies, was up 0.2% at 96.442, following a 0.7% drop on Tuesday that…
-
Incyte’s Povorcitinib Shows Promising Results in Hidradenitis Suppurativa Study
Incyte (NASDAQ:INCY) reported encouraging 24-week interim findings from its Phase 3 STOP-HS clinical trial program, evaluating povorcitinib, an oral JAK1 inhibitor, in adults with moderate to severe hidradenitis suppurativa (HS). The study revealed that patients treated with povorcitinib experienced clinically significant and meaningful improvements through Week 24. Almost 60% of participants in both povorcitinib groups…